ClinicalTrials.gg
RecruitingNCT06906549RADARUpdated Jul 23, 2025

Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis

A Phase 4 interventional study of Rituximab 200mg/6months and Rituximab 1g/6months in Rheumatoid Arthritis (RA) and Rituximab (RTx), sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by University Hospital, Strasbourg, France · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.

Planned enrollment
20th of 63
260 · median 159
Started
2025
with 1 other
Phase 4
14 of 63
3 open now
Registered
61st of 63
by date

Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 20th largest by planned enrollment, is one of 2 that started in 2025, is one of 14 in phase 4, and was the 61st registered.

Arthritis, Rheumatoid

3,338 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing rituximab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting joints and causing progressive disability. Current treatment strategies involve conventional disease-modifying anti-rheumatic drugs (csDMARDs) and, in more resistant cases, biologic DMARDs (bDMARDs) such as Rituximab. Rituximab, a monoclonal antibody targeting CD20-positive B cells, is administered as an induction dose followed by maintenance therapy every six months. Standard maintenance dosing consists of 1g infusions, but lower doses may provide equivalent efficacy with fewer side effects.

The RADAR trial is a multicenter, prospective, randomized, double-blinded, non-inferiority controlled trial designed to evaluate whether a 200 mg maintenance dose of Rituximab every six months is non-inferior to the standard 1g dose in patients with RA who are in low disease activity. The study will assess disease activity using the DAS28-CRP score over 12 months, alongside various secondary endpoints, including treatment failure rates, immune responses, and adverse events.

By determining the minimum effective Rituximab dose, the study aims to optimize patient safety, reduce the risk of infections, and lower healthcare costs. This trial is particularly relevant as Rituximab has lost patent protection, making cost-effective treatment crucial, especially in low-resource settings. Findings from this study could lead to updated treatment guidelines, benefiting RA patients worldwide.

Read the detailed description

Rheumatoid arthritis (RA) is the most prevalent chronic inflammatory rheumatic disease in Europe, affecting 0.3%-0.5% of the population. Treatment follows a Treat-to-Target (T2T) approach, where patients are initially managed with conventional synthetic DMARDs (csDMARDs), such as methotrexate, and if necessary, escalated to biologic DMARDs (bDMARDs) like Rituximab, a monoclonal antibody that depletes CD20-positive B cells.

The current standard maintenance therapy for RA patients receiving Rituximab consists of 1g infusions every six months. However, concerns about long-term safety, immune suppression, and cost have led researchers to explore lower doses. Studies suggest that 200 mg of Rituximab may be sufficient to maintain disease control while potentially reducing the risks associated with B-cell depletion, such as hypogammaglobulinemia and serious infections.

Study Rationale and Objectives The RADAR trial aims to provide definitive evidence on the feasibility of reducing Rituximab doses without compromising efficacy. A previous randomized trial indicated that a 500 mg dose was non-inferior to 1g, but the 200 mg arm lacked sufficient statistical power. Subsequent long-term follow-up data suggest that 200 mg may also be effective, warranting further investigation.

The primary objective of this study is to demonstrate that the 200 mg Rituximab maintenance dose is non-inferior to 1g in terms of disease activity, measured by DAS28-CRP at 12 months.

Secondary objectives include:

  • Comparing disease activity at 6 and 12 months
  • Evaluating treatment failure rates (need for additional Rituximab doses, switching to other bDMARDs, corticosteroid use)
  • Assessing flare occurrence and patient-reported outcomes (quality of life, disability index)
  • Investigating B and T lymphocyte subpopulations and immunoglobulin levels (IgG, IgA, IgM)
  • Analyzing vaccine responses and Human Anti-Chimeric Antibody (HACA) levels
  • Monitoring immunosuppression markers, such as Torque Teno Virus (TTV) viral load
  • Documenting adverse and serious adverse events Study Design

This is a multicenter, double-blinded, non-inferiority, randomized controlled trial (RCT). Patients will be randomized 1:1 to receive either:

  1. 200 mg of Rituximab (experimental group)
  2. 1g of Rituximab (control group) Participants will receive two infusions: one at baseline (Month 0) and one at 6 months, with follow-up visits at 4, 6, 10, and 12 months. The primary endpoint is the mean reduction in DAS28-CRP between baseline and 12 months.

Blinding Procedure:

  • Infusions will be prepared in the central pharmacy to ensure identical appearance in both groups.
  • Neither patients nor clinicians will know the assigned dosage.

Inclusion criteria:

  • Adults (≥18 years) with RA (EULAR/ACR 2010 criteria)
  • Low disease activity (DAS28-CRP \<3.2) on Rituximab
  • Prior treatment with Rituximab (at least one infusion in the past year)
  • Stable on csDMARDs (if applicable)
  • Corticosteroid dose ≤10 mg/day

Non-inclusion criteria:

  • Autoimmune diseases other than RA
  • Severe infections, immunodeficiency, or uncontrolled disease
  • Active or untreated tuberculosis, hepatitis B/C
  • Pregnancy, breastfeeding, or planned pregnancy
  • Drug/alcohol addiction
  • Patients unable to give informed consent Study Assessments and Data Collection

The study will include clinical, biological, and immunological assessments:

  • DAS28-CRP scores at baseline, 6, and 12 months
  • Immunological assays (B/T cell phenotyping, immunoglobulin levels, HACA)
  • Vaccine serologies (Diphtheria, Pneumococcus, Tetanus, Haemophilus, SARS-CoV-2)
  • Quality-of-life surveys (EQ-5D-5L, SF-36, RAPID-3)
  • Adverse event monitoring

Sample Size Calculation:

The trial requires 260 patients to achieve 92% power to detect non-inferiority, using a linear mixed model with a non-inferiority margin of -0.3 on DAS28-CRP.

Expected Impact

If 200 mg of Rituximab proves non-inferior to 1g, this study could redefine maintenance therapy guidelines, reducing:

  • Drug exposure and immune suppression risks
  • Serious infections and adverse events
  • Healthcare costs, improving access in resource-limited settings By providing definitive clinical and immunological data, the RADAR trial has the potential to influence global RA management and enhance long-term treatment safety.
03

Conditions studied

  • Rheumatoid Arthritis (RA)
  • Rituximab (RTx)

Keywords

  • Dose reduction
  • Low dose Rituximab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Diagnosis of rheumatoid arthritis (RA) according to EULAR/ACR 2010 classification criteria
  • DAS28 ≤ 5.1
  • Current maintenance treatment with Rituximab regardless of dose and/or duration of Rituximab treatment and with at least first cycle of Rituximab ended (2 initial infusions)
  • Last Rituximab infusion between 6 and 18 months prior to inclusion
  • ≤10 mg/day within 4 weeks prior to inclusion
  • Affiliation to a social insurance system or beneficiary
  • Written to participate in the study, dated and signed before starting the trial
  • Effective method of during the study

Exclusion criteria

Exclusion Criteria:

  • Rheumatic disease other than RA (except associated Sjogren's disease, which is allowed)
  • Concurrent treatment with any other targeted therapy than Rituximab
  • Any to Rituximab or to NaCl 0.9%
  • Significant uncontrolled associated disease or comorbidity
  • Known active infection or history of serious recurrent or chronic infection
  • Laboratory findings: active or untreated latent tuberculosis, positive, positive, \<8 g/dL, neutropenia \< 1.5G/L, IgM \<0.4 g/L and/or IgG \<5 g/L
  • Pregnancy, breastfeeding, or planned pregnancy during the study (on subject declaration)
  • Drug addiction, alcohol addiction
  • Patients who cannot be followed for the 12 month-duration
  • Patients over the age of legal majority who are protected, or deprived of liberty by judicial or administrative decision
  • Subject in exclusion period (determined by a previous or ongoing study)
  • Patients unable to give (e.g., patients in a situation of medical emergency, patients who have difficulty comprehending the essential details of the trial...)
  • Patients who have difficulty reading or understanding French, or who have an inability to understand the delivered information
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
260 participants (estimated)

Study arms

  • Experimental
    Rituximab 200mg/6months

    Drug: Rituximab 200mg/6months

  • Active comparator
    Rituximab 1g/6 months

    Drug: Rituximab 1g/6months

Interventions

06

What researchers measure

Primary outcomes

  1. Mean reduction of rheumatoid arthritis activity score (DAS28-CRP)

    Mean reduction of rheumatoid arthritis activity score (DAS28-CRP) between inclusion and 12 months to show non-inferiority of the lower dose.

    Time frame: 12 Months

Secondary outcomes

  1. Compare the disease activity measured by DAS28-CRP between the two arms

    Time frame: at inclusion, 6 and 12 months

  2. DAS28 categories

    Remission: DAS28 \< 2.6 ; Low Disease Activity: 2.6 ≤ DAS28 ≤ 3.2 ; Moderate Activity: 3.2 \< DAS28 ≤ 5.1; High Disease Activity: DAS28 \> 5.1 ; Boolean Remission Criteria defined as tender joint count (TJC) ≤ 1, swollen joint count (SJC) ≤ 1, CRP (mg/dL) ≤ 1, Patient global assessment (on a 0-10 scale) ≤ 1

    Time frame: at inclusion, 6 months and 12 months

  3. Number of Rituximab infusions

    Time frame: 12 Months

  4. Number of patients switching or initiating a cDMARD or switching from Rituximab to another bDMARD

    Time frame: 12 Months

  5. Number of patients using oral corticosteroids at a dose greater than 10 mg/day

    Time frame: 12 Months

  6. Number of flares throughout study period

    Time frame: 12 Months

  7. FLARE questionnaire (FLARE ASSESSMENT IN RHEUMATOID ARTHRITIS)

    FLARE-RA is a self-administered questionnaire that was developed to help identify patients who had flare in the interval between 2 rheumatology consultations. To establish a threshold for the FLARE-RA score to identify RA flare.

    Time frame: at 6 and 12 months

  8. RAPID-3 score (ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3)

    RAPID3 : Index to asses and monitor patients with RA

    Time frame: at inclusion, 6 and 12 months

  9. RAID score (RHEUMATOID ARTHRITIS IMPACT OF DISEASE)

    The Rheumatoid Arthritis Impact of Disease (RAID) score is a EULAR-initiated PROM developed in collaboration with patients with RA. It is a global composite measure of the impact of RA that takes into account: pain, physical disability, fatigue, sleep disturbances, coping as well as physical and emotional well-being. The RAID score was calculated using the online EULAR toolkit. Each of the seven individual domains of the RAID is scored on a 10-item numerical rating scale, with zero being a good or low activity score and 10 a high or severe activity score. In the absence of guidance, we arbitrarily classified the numerical rating scale results into one of three equivalent-sized ranges (mild: 0-2; moderate: 3-6; severe: 7-10) to give an overall idea of which domains scored particularly poorly or well.

    Time frame: at inclusion, 6 and 12 months

  10. EQ5D-5L (EUROQOL GROUP)

    The EQ-5D family of instruments has been developed to describe and value health across a wide range of disease areas. They are frequently used in research into health in the general population. There are three versions of the instrument: EQ-5D-5L, EQ-5D-3L and EQ-5D-Y. The EQ-5D is used worldwide and has been translated into most major languages through a closely monitored translation process. The 5-level EQ-5D version (EQ-5D-5L) consists of 2 tests: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). * The EQ-5D-5L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. * The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' =100 and 'Worst imaginable health state'=0.

    Time frame: at inclusion, 6 and 12 months

  11. SF-36 to compare the patient quality of life

    SF-36 (MEDICAL OUTCOMES STUDY SHORT FORM HEALTH SURVEY 36 - RAND CORPORATION)

    Time frame: at inclusion, 6 and 12 months

  12. B, T and NK cell phenotyping to compare cell subpopulations

    Time frame: at inclusion, 6 and 12 months

  13. Compare change in IgG, IgA and IgM levels

    Time frame: at inclusion, 6 and 12 months

  14. Vaccinal serologies to compare vaccine response

    Diphteria, pneumococcus, tetanus, Haemophilus influenzae type B and SARS-CoV-2

    Time frame: at inclusion, 6 and 12 months

  15. Compare HACA (Human antichimeric antibody) levels

    Time frame: at inclusion and 12 months

  16. Evolution of Torque Teno Virus (TTV) viral load in the serum of patients

    Time frame: between inclusion and 12 months

  17. Number of infections

    Time frame: 12 Months

  18. Number of serious infections

    Time frame: 12 Months

  19. Number of adverse events

    Time frame: 12 Months

  20. Number ofserious adverse events

    Time frame: 12 Months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jul 2026, 12 months after the start.

Of 79 non-industry phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 92. This study's planned 12 months is below that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Apr 2, 2025
StartActual
Jul 11, 2025
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06906549
Responsible party
Sponsor
First posted
Apr 2, 2025
Start date
Jul 11, 2025
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Jul 23, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion